Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities

M.E. Lacouture; M.J. Anadkat; R.J. Bensadoun; J. Bryce; A. Chan; J.B. Epstein; B. Eaby-Sandy; B.A. Murphy; A. Barasch; C. Beder; C.B. Boers-Doets; T. Doherty; J.E. Raber-Durlacher; D. Forstner; S. Langer; J. Lees; D. Mellor

doi:10.1007/s00520-011-1197-6

Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities

M.E. Lacouture, M.J. Anadkat, R.J. Bensadoun, J. Bryce, A. Chan, J.B. Epstein, B. Eaby-Sandy, B.A. Murphy, A. Barasch, C. Beder, C.B. Boers-Doets, T. Doherty, J.E. Raber-Durlacher, D. Forstner, S. Langer, J. Lees, D. Mellor

Periodontology

Research output: Contribution to Journal › Article › Academic › peer-review

Abstract

Background
Epidermal growth factor receptor inhibitors (EGFRI) produce various dermatologic side effects in the majority of patients, and guidelines are crucial for the prevention and treatment of these untoward events. The purpose of this panel was to develop evidence-based recommendations for EGFRI-associated dermatologic toxicities.

Methods
A multinational, interdisciplinary panel of experts in supportive care in cancer reviewed pertinent studies using established criteria in order to develop first-generation recommendations for EGFRI-associated dermatologic toxicities.

Results
Prophylactic and reactive recommendations for papulopustular (acneiform) rash, hair changes, radiation dermatitis, pruritus, mucositis, xerosis/fissures, and paronychia are presented, as well as general dermatologic recommendations when possible.

Conclusion
Prevention and management of EGFRI-related dermatologic toxicities is critical to maintain patients’ health-related quality of life and dose intensity of antineoplastic regimens. More rigorous investigation of these toxicities is warranted to improve preventive and treatment strategies.

Original language	English
Pages (from-to)	1079-1095
Journal	Supportive Care in Cancer
Volume	19
Issue number	8
DOIs	https://doi.org/10.1007/s00520-011-1197-6
Publication status	Published - 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00520-011-1197-6

Persistent URL (handle)

Copy link address

Cite this

Lacouture, M. E., Anadkat, M. J., Bensadoun, R. J., Bryce, J., Chan, A., Epstein, J. B., Eaby-Sandy, B., Murphy, B. A., Barasch, A., Beder, C., Boers-Doets, C. B., Doherty, T., Raber-Durlacher, J. E., Forstner, D., Langer, S., Lees, J., & Mellor, D. (2011). Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Supportive Care in Cancer, 19(8), 1079-1095. https://doi.org/10.1007/s00520-011-1197-6

@article{1305fff691ca48f2994e246ba7441afb,

title = "Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities",

abstract = "BackgroundEpidermal growth factor receptor inhibitors (EGFRI) produce various dermatologic side effects in the majority of patients, and guidelines are crucial for the prevention and treatment of these untoward events. The purpose of this panel was to develop evidence-based recommendations for EGFRI-associated dermatologic toxicities.MethodsA multinational, interdisciplinary panel of experts in supportive care in cancer reviewed pertinent studies using established criteria in order to develop first-generation recommendations for EGFRI-associated dermatologic toxicities.ResultsProphylactic and reactive recommendations for papulopustular (acneiform) rash, hair changes, radiation dermatitis, pruritus, mucositis, xerosis/fissures, and paronychia are presented, as well as general dermatologic recommendations when possible.ConclusionPrevention and management of EGFRI-related dermatologic toxicities is critical to maintain patients{\textquoteright} health-related quality of life and dose intensity of antineoplastic regimens. More rigorous investigation of these toxicities is warranted to improve preventive and treatment strategies.",

author = "M.E. Lacouture and M.J. Anadkat and R.J. Bensadoun and J. Bryce and A. Chan and J.B. Epstein and B. Eaby-Sandy and B.A. Murphy and A. Barasch and C. Beder and C.B. Boers-Doets and T. Doherty and J.E. Raber-Durlacher and D. Forstner and S. Langer and J. Lees and D. Mellor",

year = "2011",

doi = "10.1007/s00520-011-1197-6",

language = "English",

volume = "19",

pages = "1079--1095",

journal = "Supportive Care in Cancer",

issn = "0941-4355",

publisher = "Springer Verlag",

number = "8",

}

Lacouture, ME, Anadkat, MJ, Bensadoun, RJ, Bryce, J, Chan, A, Epstein, JB, Eaby-Sandy, B, Murphy, BA, Barasch, A, Beder, C, Boers-Doets, CB, Doherty, T, Raber-Durlacher, JE, Forstner, D, Langer, S, Lees, J & Mellor, D 2011, 'Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities', Supportive Care in Cancer, vol. 19, no. 8, pp. 1079-1095. https://doi.org/10.1007/s00520-011-1197-6

TY - JOUR

T1 - Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities

AU - Lacouture, M.E.

AU - Anadkat, M.J.

AU - Bensadoun, R.J.

AU - Bryce, J.

AU - Chan, A.

AU - Epstein, J.B.

AU - Eaby-Sandy, B.

AU - Murphy, B.A.

AU - Barasch, A.

AU - Beder, C.

AU - Boers-Doets, C.B.

AU - Doherty, T.

AU - Raber-Durlacher, J.E.

AU - Forstner, D.

AU - Langer, S.

AU - Lees, J.

AU - Mellor, D.

PY - 2011

Y1 - 2011

N2 - BackgroundEpidermal growth factor receptor inhibitors (EGFRI) produce various dermatologic side effects in the majority of patients, and guidelines are crucial for the prevention and treatment of these untoward events. The purpose of this panel was to develop evidence-based recommendations for EGFRI-associated dermatologic toxicities.MethodsA multinational, interdisciplinary panel of experts in supportive care in cancer reviewed pertinent studies using established criteria in order to develop first-generation recommendations for EGFRI-associated dermatologic toxicities.ResultsProphylactic and reactive recommendations for papulopustular (acneiform) rash, hair changes, radiation dermatitis, pruritus, mucositis, xerosis/fissures, and paronychia are presented, as well as general dermatologic recommendations when possible.ConclusionPrevention and management of EGFRI-related dermatologic toxicities is critical to maintain patients’ health-related quality of life and dose intensity of antineoplastic regimens. More rigorous investigation of these toxicities is warranted to improve preventive and treatment strategies.

AB - BackgroundEpidermal growth factor receptor inhibitors (EGFRI) produce various dermatologic side effects in the majority of patients, and guidelines are crucial for the prevention and treatment of these untoward events. The purpose of this panel was to develop evidence-based recommendations for EGFRI-associated dermatologic toxicities.MethodsA multinational, interdisciplinary panel of experts in supportive care in cancer reviewed pertinent studies using established criteria in order to develop first-generation recommendations for EGFRI-associated dermatologic toxicities.ResultsProphylactic and reactive recommendations for papulopustular (acneiform) rash, hair changes, radiation dermatitis, pruritus, mucositis, xerosis/fissures, and paronychia are presented, as well as general dermatologic recommendations when possible.ConclusionPrevention and management of EGFRI-related dermatologic toxicities is critical to maintain patients’ health-related quality of life and dose intensity of antineoplastic regimens. More rigorous investigation of these toxicities is warranted to improve preventive and treatment strategies.

U2 - 10.1007/s00520-011-1197-6

DO - 10.1007/s00520-011-1197-6

M3 - Article

SN - 0941-4355

VL - 19

SP - 1079

EP - 1095

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

IS - 8

ER -

Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities

Abstract

UN SDGs

Access to Document

Persistent URL (handle)

Fingerprint

Cite this